# VaxInnate Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vaxinnate

- Industry: Biotechnology
- Headquarters: US
- Website: www.vaxinnate.com
- Total disclosed funding: $121M
- Latest round: Series A (Sep 25, 2014)
- Investors on record: 7

## About

Founded in 2001 and based in New Jersey, US, VaxInnate Corporation is a pharmaceutical company that focuses on developing vaccines for the treatment of pandemic and seasonal influenza.

## Funding rounds

- Series A, Sep 25, 2014, $6M — Canaan Partners
- Series D, May 5, 2009, $30M — CHL Medical Partners, HealthCare Ventures, Oxford Bioscience Partners, Wellcome Trust, Canaan Partners, New Leaf Venture Partners, MedImmune Ventures
- Series C, Apr 8, 2008, $20M — CHL Medical Partners, HealthCare Ventures, Oxford Bioscience Partners, Canaan Partners
- Series C, Oct 25, 2006, $40M — CHL Medical Partners, HealthCare Ventures, Oxford Bioscience Partners, Canaan Partners, New Leaf Venture Partners, MedImmune Ventures
- Series B, Mar 11, 2004, $23M — CHL Medical Partners, HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures
- Series A, May 1, 2002, $1.5M — CHL Medical Partners

## Investors

- CHL Medical Partners (https://capitalatlas.ai/funds/chl-medical-partners) — Series A, Series B, Series C, Series D
- HealthCare Ventures — Series B, Series C, Series D
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series B, Series C, Series D
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series B, Series C, Series D
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series C, Series D, Series A
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series C, Series D
- Wellcome Trust — Series D